Folate, Vitamin B12 and Homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center

Aline Barnabé1*, Ana Cláudia Morandi Aléssio2, Luis Fernando Bittar2, Bruna de Moraes Mazetto2, Angélica M Bicudo3, Erich V de Paula1, Nelci Fenalti Höehr1 and Joyce M Annichino-Bizzacchi2

Abstract

Background: Folate and vitamin B12 are essential nutrients, whose deficiencies are considerable public health problems worldwide, affecting all age groups. Low levels of these vitamins have been associated with high concentrations of homocysteine (Hcy) and can lead to health complications. Several genetic polymorphisms affect the metabolism of these vitamins. The aims of this study were to assess folate, vitamin B12 and homocysteine status in distinct Brazilian individuals after the initiation of folic acid fortification by Brazilian authorities and to investigate the effects of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms on folate, vitamin B12 and Hcy levels in these populations.

Methods: A total of 719 individuals including the elderly, children, as well as pregnant and lactating women were recruited from our health care center. Folate, vitamin B12 and Hcy levels were measured by conventional methods. Genotype analyses of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms were performed by PCR-RFLP.

Results: The overall prevalence of folate and vitamin B12 deficiencies were 0.3% and 4.9%, respectively. Folate deficiency was observed only in the elderly (0.4%) and pregnant women (0.3%), whereas vitamin B12 deficiency was observed mainly in pregnant women (7.9%) and the elderly (4.2%). Plasma Hcy concentrations were significantly higher in the elderly (33.6%). Pregnant women carrying the MTHFR 677TT genotype showed lower serum folate levels (p = 0.042) and higher Hcy levels (p = 0.003). RFC1 A80G and GCPII C1561T polymorphisms did not affect folate and Hcy levels in the study group. After a multivariate analysis, Hcy levels were predicted by variables such as folate, vitamin B12, gender, age and RFC1 A80G polymorphism, according to the groups studied.

Conclusion: Our results suggest that folate deficiency is practically non-existent in the post-folic acid fortification era in the subgroups evaluated. However, screening for vitamin B12 deficiency may be particularly relevant in our population, especially in the elderly.

Keywords: Folate, Vitamin B12, Homocysteine, Folic acid fortification, Reduced folate carrier, Glutamate carboxypeptidase II, Methylenetetrahydrofolate reductase

* Correspondence: a_line00@hotmail.com
1Department of Clinical Pathology, Faculty of Medical Sciences, University of Campinas, Rua Alexander Fleming, 105, Campinas, SP 13083-881, Brazil
Full list of author information is available at the end of the article

© 2015 Barnabé et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Folate and vitamin B12 are essential nutrients, and their deficiencies represent public health problems worldwide, affecting all age groups and leading to complications such as anemia, birth defects and neurological disorders [1,2]. Low concentrations of folate and vitamin B12 are also associated with high homocysteine (Hcy) levels, considered a risk factor for cardiovascular disease, cognitive decline and adverse pregnancy outcomes [2-4]. Folate deficiency can be caused by inadequate dietary intake, medications (methotrexate and anticonvulsants), alcoholism and conditions associated with increased cell turnover. In addition, a few genetic polymorphisms have been shown to influence folate levels. On the other hand, vitamin B12 deficiency results mainly from gastrointestinal conditions leading to vitamin B12 malabsorption, and less frequently from intestinal parasitosis and genetic polymorphisms [5]. Genetic polymorphisms such as reduced folate carrier (RFC1) A80G and glutamate carboxypeptidase II (GCPII) C1561T have also been shown to impair folate transport and absorption, respectively, thus affecting the bioavailability of the dietary folate [6,7]. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with elevated Hcy levels and reduced folate and vitamin B12 levels [8,9].

Fortification of white flour with folic acid is mandatory in several countries and has proved to be a successful public health intervention. Although the major purpose of folic acid fortification is to reduce the occurrence of neural tube defects (NTD) during pregnancy, an additional benefit is a potential protection against chronic diseases, through its association with lower Hcy levels [10,11]. In Brazil, this strategy has been applied since 2004 by the National Health Surveillance Agency, ANVISA [12]. Fortification was implemented to provide an adequate intake of folate mainly for vulnerable populations, such as pregnant women, lactating women, children and the elderly [13,14].

In this context, the aims of this study were: (1) to assess folate and vitamin B12 status, as well as the frequency of elevated Hcy levels among the elderly, children, pregnant women and lactating women consecutively assisted at a public health care center after folic acid fortification; and (2) to investigate the effects of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms on folate, vitamin B12 and Hcy levels in the same study groups.

Methods
Study population
Seven hundred and nineteen participants were enrolled from April 2006 to May 2007, and divided into the following subgroups: 262 elderly individuals (≥60 year old), 106 children (≤6 year old), 291 pregnant women and 60 lactating women. The study group was chosen based on their vulnerability to vitamin deficiencies. We excluded individuals who had hypothyroidism, renal and hepatic disease, and those using agents that affect vitamin B metabolism such as methotrexate and anticonvulsants. In addition, individuals with acute illnesses were also excluded. Information regarding age, gender, height, weight, medical history, smoking, use of multivitamin supplements and gestational stage were collected.

The study groups were composed of individuals consecutively attended to at a public health care center in the northern area of the city of Campinas, Brazil, during visits to primary care physicians. Our recruitment goal was 250 individuals from each group, but due to the exclusion criteria and rate of refusal to participate this number could not be reached. Thus, all eligible participants, who were in accordance with the study protocol and who agreed to participate in the study, provided a written informed consent. For children, the written informed consent was obtained from mothers or guardians. The study protocol was approved by the Ethics Committee of the University of Campinas.

Blood collection
Fasting blood samples were obtained from all participants in tubes without anticoagulant, for measurement of folate and vitamin B12, and in tubes containing EDTA to measure Hcy levels and for the genetic analyses (RFC1 A80G, GCPII C1561T and MTHFR C677T). Serum and plasma samples were processed within 3 hours of collection and stored below −80°C until analyses.

Laboratory assays
Serum levels of folate and vitamin B12 were determined using chemiluminescence immunoassays (Elecsys/Roche Diagnostics, Mannheim, Germany). Hcy in plasma was assessed by high-performance liquid chromatography (HPLC) with fluorescence detection [15]. Genomic DNA was isolated from whole blood by standard methods. The analyses of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms were accomplished by PCR-RFLP. The amplified fragments were digested by restriction enzymes (HinfI, HhaI and Accl, respectively), as previously described [6,16,17].

We separated folate, vitamin B12 and Hcy levels into categories, based on the reference values used in our service. For folate levels, categories were: <4 ng/mL, ≥4 ng/mL; for vitamin B12: <200 pg/mL, 200 – 300 pg/mL, >300 pg/mL; and for Hcy levels, these categories were: <15 μmol/L, ≥15 μmol/L. Individuals with levels of folate below 4 ng/mL and vitamin B12 below 200 pg/mL were categorized as having deficiency. Vitamin B12 levels between 200 – 300 pg/mL were considered as marginal status [5,14].
Levels of Hcy ≥15 μmol/L were considered elevated [18]. It is noteworthy that the reference values used to describe folate and vitamin B12 deficiencies are similar to those cited by WHO [19].

**Statistical analysis**

Data are expressed as median, percentiles 25 and 75, absolute number and percentages. Medians were compared using the Mann–Whitney test for 2-group comparisons and the Kruskal-Wallis test for 3-group comparisons. The Hardy-Weinberg equilibrium test was performed for all genotypes using the chi-square test. Multiple linear regression analysis with stepwise criteria was performed for Hcy as the dependent variable and folate, vitamin B12, polymorphisms, age, gender, body mass index, hypertension, diabetes and smoking as the independent variables. This analysis was adjusted for gestational stage in pregnant women. Statistical tests were performed using SPSS software for Windows version 17.0 (SPSS Inc, Chicago, IL, USA) and SAS System for Windows version 9.2 (SAS Institute Inc, Cary, NC, USA) with the level of significance set at p < 0.05.

**Results**

During the enrollment period, all individuals who assisted at a public health care center were invited to participate in the study. A total of 719 individuals were included in our study. Among them, 40.5% were pregnant women, 36.5% were elderly, 14.7% were children and 8.3% were lactating women. The demographic characteristics of the studied population are summarized in Table 1.

| Table 1 Demographic characteristics of the study population |
|------------------------------------------------------------|
| **Elderly (N = 262)**                                      |
| Age (y) 167 (60 – 91)                                      |
| Gender (male) 114                                         |
| BMI (mean ± SD) 26.7 (23.9, 29.9)                          |
| Supplementation 43 (16.4)                                 |
| Smoking 20 (7.6)                                          |
| Hypertension 158 (60.3)                                   |
| Diabetes 65 (24.8)                                        |
| Dyslipidemia 65 (24.8)                                    |
| Gestational stage 73 (27)                                 |
| **Children (N = 106)**                                   |
| Age (y) 3 (05 - 6)                                        |
| Gender (male) 54                                          |
| BMI (mean ± SD) 15.9 (14.8, 17.9)                         |
| Supplementation 22 (16.6)                                 |
| Smoking -                                                |
| Hypertension -                                           |
| Diabetes 3 (2.8)                                         |
| Dyslipidemia -                                           |
| Gestational stage -                                      |
| **Pregnant women (N = 291)**                             |
| Age (y) 26 (14–43)                                       |
| Gender (male) -                                          |
| BMI (mean ± SD) 26.4 (23.4, 30.7)                         |
| Supplementation 138 (47.4)                               |
| Smoking 27 (9.3)                                         |
| Hypertension 42 (14.4)                                    |
| Diabetes 12 (4.1)                                        |
| Dyslipidemia 2 (0.7)                                     |
| Gestational stage 73 (27.8)                               |
| **Lactating women (N = 60)**                             |
| Age (y) 26.5 (14–40)                                      |
| Gender (male) -                                          |
| BMI (mean ± SD) 23.4 (21.5, 26.4)                         |
| Supplementation 10 (16.6)                                |
| Smoking 8 (13.3)                                         |
| Hypertension 5 (8.3)                                     |
| Diabetes 1 (1.6)                                         |
| Dyslipidemia -                                           |
| Gestational stage -                                      |

Age is expressed as median and range in parentheses. Body Mass Index (BMI) is expressed as median and percentiles (25 and 75) in parentheses. Gender is expressed as number of individuals.

1 Users of multivitamins or folic acid supplements.

2 Hypertension definition: blood pressure exceeding 140 over 90 mmHg.

3 Gestational stage was not available for 28 pregnant women.

**Folate, vitamin B12 and homocysteine levels**

Among the distinct study groups, children had higher vitamin B12 levels, the elderly had higher Hcy levels and lactating women had lower folate levels (Table 2).

The overall frequency of folate and vitamin B12 deficiencies were estimated to be 0.3% and 4.9% respectively (Table 3). Interestingly, we observed no folate or vitamin B12 deficiencies in the children included in our study, and only 1% presented marginal status of vitamin B12. Folate deficiency could be identified in 0.4% of elderly and 0.3% of pregnant women. None of the lactating women showed folate deficiency. The pregnant women group was the one which presented a higher frequency of vitamin B12 deficiency (7.9%), followed by the elderly (4.2%) and lactating women (1.9%). Marginal status of vitamin B12 was observed in 14.5% of the elderly, 33.7% of pregnant women and 7.4% of lactating women. The frequency of elevated Hcy levels was observed mainly in the elderly (33.6%). Among pregnant and lactating women, the frequencies of elevated Hcy levels were 0.7 and 5.0%, respectively.

**Effects of polymorphisms RFC1 A80G, GCPII C1561T and MTHFR C677T in the studied population**

In order to assess the effects of polymorphisms on folate, vitamin B12 and Hcy levels we compared the median of these parameters in individuals with different genotypes (Table 4). Folate, vitamin B12 and Hcy concentrations were not affected by the RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms in the elderly, children and lactating women. Pregnant women carrying the MTHFR 677 TT genotype showed lower
serum folate levels ($p = 0.042$) and higher Hcy levels ($p = 0.003$).

Homozygosity for the GCPII C1561T polymorphism was not found in our population.

Genotype distributions of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms were in Hardy-Weinberg equilibrium. Table 5 summarizes the frequencies of genotypes for each polymorphism studied.

Impact of clinical and laboratory parameters on Hcy levels

We next evaluated the impact of clinical and laboratory parameters on Hcy levels (Table 6). Using a multiple linear regression analysis with stepwise criteria, the variables independently associated with Hcy levels were: folate, vitamin B12, gender, age and RFC1 A80G polymorphism (genotype AA) in the elderly; vitamin B12 in children; and folate in pregnant women. None of the variables evaluated showed any impact on Hcy levels in lactating women.

Table 2 Folate, vitamin B12, and Hcy levels in different study groups

| Groups         | Folate (ng/mL) | Vitamin B12 (pg/mL) | Hcy$^1$ (μmol/L) |
|---------------|--------------|---------------------|------------------|
| Elderly       | 11.2(8.7, 13.6) | 443(333, 620.2)     | 13.5(11.1, 17.1) |
| N = 262       | N = 262      | N = 262             |
| Children      | 12.4(9.4, 14.6) | 853.0(611, 1188)    | 6.2(5.2, 7.3)    |
| N = 103       | N = 103      | N = 105             |
| Pregnant women| 10.7(8.3, 14.1) | 325.0(257, 424)     | 6.4(5.3, 7.5)    |
| N = 291       | N = 291      | N = 291             |
| Lactating women| 9.8(7.6, 12.2)| 523.0(415.7, 641.5) | 9.2(7.6, 10.8)   |
| N = 54        | N = 54       | N = 60              |
| $p^2$         | 0.003        | p < 0.001           | p < 0.001        |

All values are expressed as median and percentiles (25 and 75).

$^1$Hcy, homocysteine.

$^2$Kruskal-Wallis test.

Discussion

The present study suggests that fortification of flour with folic acid has been effective, as folate deficiency was practically nonexistent (0.3%), whereas vitamin B12 deficiency was present in 4.9% of the studied group. A previous study performed with Brazilian adults reported that folate deficiency was not detected and vitamin B12 deficiency was over 6% [20]. Similarly, folate deficiency is practically nonexistent and vitamin B12 deficiency is approximately 5% in the Canadian population [11]. In developed countries, folate deficiency is uncommon; however this deficiency can still be observed in some developing countries [21]. In addition, the prevalence of folate and vitamin B12 deficiencies vary between different studies due to differences in the assays employed [13].

We believe that our results represent the profile of these vitamins in the investigated group, as the measurements were performed in 719 individuals of various ages under several clinical conditions using laboratory methods considered suitable for analysis. Furthermore, the subgroup-specific evaluation is also important, enabling the identification of individuals at an increased risk of developing vitamin deficiencies. These individuals should be considered for specific prophylactic measures, as a problem in clinical practice is that sometimes the deficiencies are identified only when complications, such as anemia, NTD, and neurological disorders, have already occurred. Thus, prevention of folate and vitamin B12 deficiencies becomes a major challenge for health worldwide.

As described previously, folate deficiency may occur at any age, mostly in individuals ingesting a poor diet or suffering from intestinal malabsorption [22]. Moreover, vitamin B12 levels frequently decrease with age due to malabsorption of vitamins from food, which is more common in the elderly [11]. Approximately 10% of the elderly are estimated to present reduced levels of vitamin B12, with this prevalence increasing approximately 5% at the age of 65 years and to 20% at the age of

Table 3 Folate, vitamin B12 and Hcy status according to cut-off values

| Cut-off values | All N, % | Elderly N, % | Children N, % | Pregnant women N, % | Lactating women N, % |
|---------------|---------|-------------|--------------|---------------------|---------------------|
| **Folate**    |         |             |              |                     |                     |
| <4 ng/mL      | 2, 0.3  | 1, 0.4      | -            | 1, 0.3              | -                   |
| ≥4 ng/mL      | 708, 99.7 | 261, 99.6   | 103, 100     | 290, 99.7           | 54, 100             |
| **Vitamin B12** |       |             |              |                     |                     |
| <200 pg/mL    | 35, 4.9 | 11, 4.2     | -            | 23, 7.9             | 1, 1.9              |
| 200 - 300 pg/mL | 141, 19.9 | 38, 14.5   | 1, 1.0       | 98, 33.7            | 4, 7.4              |
| ≥300 pg/mL    | 534, 75.2 | 213, 81.3   | 102, 99.0    | 170, 58.4           | 49, 90.7            |
| **Homocysteine** |       |             |              |                     |                     |
| <15 μmol/L    | 625, 87.0 | 174, 66.4   | 105, 100     | 289, 99.3           | 57, 95.0            |
| ≥15 μmol/L    | 93, 13.0 | 88, 33.6    | -            | 2, 0.7              | 3, 5.0              |
Table 4 Folate, vitamin B12 and Hcy levels according to different polymorphisms in the study groups

| GROUPS          | RFC1 A80G³ | GCPII C1651T⁴ | MTHFR C677T⁵ | p³  |
|-----------------|------------|---------------|--------------|-----|
|                 | AA  | AG  | GG  | CC  | CT  | CC  | CT  | TT  |     |
| **Folate (ng/mL)** |     |     |     |     |     |     |     |     |     |
| Elderly         |      |     |     |     |     |     |     |     |     |
| N = 49          | 11.2 (8.4,13.2) | 11.2 (8.8, 13.9) | 11 (8.6, 13.2) | 0.840 | 11 (8.5, 13.7) | 12.2 (11.1, 13) | 0.252 | 11.2 (8.6, 13.3) | 11 (8.8, 14.2) | 10.2 (7.3, 12.4) | 0.158 |
| N = 125         | 12.5 (8.2,16.1) | 125 (9.4, 15.1) | 125 (10.2, 14.1) | 0.863 | 12 (9.4, 15.1) | 11.5 (8.2, 18.3) | 0.932 | 12.0 (9.3, 14.4) | 12.5 (9.2, 14.9) | 13.8 (9.6, 15.6) | 0.441 |
| N = 60          | 9.8 (8.0,13.6) | 11 (8.4, 15) | 10.9 (8.5, 14.2) | 0.346 | 108 (8.2, 14.3) | 11.5 (8.5, 13.3) | 0.927 | 11.2 (9.1, 15) | 10.7 (7.7, 14) | 8.8 (7.3, 11.6) | 0.042 |
| N = 74          | 10.6 (9.4,12.7) | 9.5 (7, 12.1) | 9.5 (7.3, 11.7) | 0.300 | 9.8 (7.7, 12) | 12.6 (7.5, 14.3) | 0.429 | 10 (9.1, 12.5) | 9.3 (7.1, 13.1) | 9.7 (6.8, 10.8) | 0.723 |
| **Vitamin B12 (pg/mL)** |     |     |     |     |     |     |     |     |     |
| Elderly         |      |     |     |     |     |     |     |     |     |
| N = 49          | 418 (310, 687.5) | 446 (341, 623) | 442 (337.5, 584.7) | 0.650 | 444 (333, 616.5) | 373.5 (288.2, 647.7) | 0.317 | 463 (345, 594) | 431 (330.5, 627.5) | 391.5 (276.2, 577.5) | 0.443 |
| N = 125         | 827 (638.5, 1047.5) | 874 (650.2, 1200) | 770.5 (513, 1207.2) | 0.840 | 901 (611, 1204) | 772.5 (518.7, 1000.5) | 0.359 | 790 (572, 1109) | 918.5 (660.2, 1206) | 756 (553, 1049) | 0.333 |
| N = 60          | 341.5 (267.7, 462) | 324 (253, 419) | 319 (240, 412) | 0.218 | 322 (253.7, 424) | 324 (263.5, 399.5) | 0.738 | 321 (249, 420) | 334 (257.5, 425) | 308.5 (236.2, 441.7) | 0.703 |
| N = 74          | 563 (470, 648) | 467 (400.2, 540.7) | 624 (408.7, 682) | 0.114 | 488 (414, 622.5) | 627 (576, 699) | 0.094 | 488 (437, 627) | 485 (377, 551.5) | 617 (520, 712) | 0.137 |
| **Homocysteine (μmol/L)** |     |     |     |     |     |     |     |     |     |
| Elderly         |      |     |     |     |     |     |     |     |     |
| N = 49          | 14.1 (11.7, 17.9) | 12.9 (10.7, 16.4) | 13.8 (11.4, 17.2) | 0.170 | 13.5 (11.2, 17.1) | 13.3 (10.7, 18.4) | 0.896 | 13.2 (10.9, 15.7) | 13.3 (10.8, 17.2) | 14.8 (12.1, 18.4) | 0.087 |
| N = 125         | 6.0 (5.3, 6.7) | 6.3 (5.1, 7.4) | 6.7 (5.2, 7.4) | 0.582 | 6.2 (5.2, 7.1) | 5.9 (5.2, 8.4) | 0.876 | 6.2 (5.4, 7.2) | 5.8 (4.9, 7.5) | 6.8 (6.5, 8) | 0.099 |
| N = 60          | 5.9 (5.1, 7.6) | 6.4 (5.4, 7.6) | 6.3 (5.5, 7.5) | 0.151 | 6.4 (5.4, 7.5) | 6.2 (5.1, 7.8) | 0.710 | 6.2 (5.4, 7.4) | 6.3 (5.2, 7.3) | 7.8 (6.3, 9.2) | 0.003 |
| N = 74          | 9.4 (8.2, 10.4) | 9.7 (7.4, 11.5) | 8.7 (7.8, 10.9) | 0.929 | 9.4 (7.5, 10.8) | 12.6 (8.9, 12.6) | 0.193 | 9.4 (7.6, 10.7) | 9.9 (8, 11.9) | 7.8 (6.8, 11.4) | 0.529 |

Values are expressed as median and percentiles (25 and 75).

1Kruskal-Wallis test.
2Mann-Whitney test.
3AA, wild type; AG, heterozygous; and GG homozygous mutant for the RFC1 A80G polymorphism.
4CC, wild type; and CT, heterozygous for the GCPII C1561T polymorphism.
5CC, wild type; CT, heterozygous; and TT, homozygous mutant for the MTHFR C677T polymorphism.
Table 5 Overall genotype frequencies of RFC1 A80G, GCPII C1561T and MTHFR C677T polymorphisms

| Polymorphisms | Genotypes | Study groups |
|---------------|-----------|--------------|
|               | N         | %            |
| RFC1 A80G1   |           |              |
| AA           | 158       | 22.3         |
| AG           | 343       | 48.4         |
| GG           | 207       | 29.3         |
| GCPII C1561T2|           |              |
| CC           | 619       | 93.4         |
| CT           | 44        | 6.6          |
| MTHFR C677T3 |           |              |
| CC           | 326       | 47.3         |
| CT           | 286       | 41.5         |
| TT           | 77        | 11.2         |

1AA, wild type; GA, heterozygous; and GG homozygous mutant for the RFC1 A80G polymorphism.
2CC, wild type; and CT, heterozygous for the GCPII C1561T polymorphism.
3CC, wild type; CT, heterozygous; and TT, homozygous mutant for the MTHFR C677T polymorphism.

85 years [13,18]. In our study, we identified 0.4% and 4.2% of the elderly with folate and vitamin B12 deficiencies respectively, whereas 14.5% showed marginal levels of vitamin B12. Coussirat et al. evaluated 545 Brazilian elderly individuals, and detected 0.5% with folate deficiency, 5.5% with vitamin B12 deficiency, while 23.3% had marginal levels of vitamin B12. Xavier et al. showed that 7.2% of the elderly had a vitamin B12 deficiency [20,23].

Our results show a situation that can often go unnoticed in the elderly, which is a vitamin B12 deficiency.

Table 6 Predictors of Hcy levels in the elderly, children and pregnant women

| Groups          | Independent variables | β    | R²  | P     |
|-----------------|-----------------------|------|-----|-------|
| Elderly         |                       |      |     |       |
|                 | Folate                | −4.594 | 0.0441 | p < 0.001 |
|                 | Vitamin B12           | −0.044 | 0.0324 | p < 0.001 |
|                 | Gender (male)         | 52.785 | 0.1622 | p < 0.001 |
|                 | Age                   | 3.219  | 0.0716 | p < 0.001 |
|                 | RFC1 (AG x AA)        | −26.995 | 0.0192 | 0.011 |
|                 | (GG x AA)             | −11.736 |       |       |
| Children        |                       |      |     |       |
|                 | Vitamin B12           | −0.23  | 0.0782 | 0.011 |
| Pregnant women  |                       |      |     |       |
|                 | Folate                | −4.556 | 0.0750 | p < 0.001 |

Multiple linear regression analysis with stepwise criteria. Independent variables: age, gender (male versus female), smoking, hypertension, diabetes, dyslipidemia, BMI, polymorphisms (RFC1 A80G, GCPII C1561T e MTHFR C677T), folate and vitamin B12. In pregnant women, the analysis was adjusted for gestational stage.

Atrophy of the gastric mucosa, the presence of auto-antibodies against intrinsic factors (often undiagnosed), or the presence of *H. pylori* may play a role as an etiological factor of vitamin B12 deficiency in this age group, because it results in malabsorption of vitamin B12.

Although almost all of these individuals in our study showed no anemia (data not shown), it should be emphasized that symptoms such as depression, dementia and impaired cognitive function, which have been associated with vitamin B12 deficiency, may be misinterpreted as aging-related co-morbidities rather than vitamin B12 dependent co-morbidities [24–26]. In this sense, our findings have great relevance in clinical practice, suggesting that the measurement of this vitamin should be part of routine diagnosis in patients over 60 years, even in the absence of hematological symptoms. The high frequency of elderly individuals with marginal levels of vitamin B12 is another important fact, although the clinical significance of these levels on their health are not clear [27].

Children aged from 0.5 – 6 years, included in our study, did not exhibit folate and vitamin B12 deficiencies. Several studies conducted in developing countries, such as Colombia, have described a very low prevalence of deficiency of these vitamins [28]. In Brazil, a study that included 1111 Amazonian children reported a folate and vitamin B12 deficiency of 2.5 and 3.7%, respectively [29]. Another study of 164 Brazilian children showed that deficiency of folate and vitamin B12 were present in 2.2 and 11.7%, respectively. It is important to note that this study included children under 2 years of age, who continued to receive cow’s milk and porridge or did not consume vegetables, fruits, and animal products until over the age of one; a fact that might have contributed to the high prevalence of vitamin B12 deficiency [30]. Shakur et al. showed that since food fortification with folic acid, folate deficiency has been reduced to practically 0% in children aged 1 – 14 years in Canada [31]. These results suggest that there is apparently no additional advantage of supplementation with folic acid in countries where food products are folic acid-fortified [14].

Our results suggest that fortification was adequate to prevent folate deficiency in these children, and that diet was capable of meeting vitamin B12 requirements. Vitamin B12 deficiency in children is exceptional as daily requirements are very small, and children normally consume food that contains this nutrient.

During pregnancy, folate and vitamin B12 are essential for normal fetal development. Furthermore, pregnant women have an increased physiological need for these nutrients, and their inadequate intake increases the risk of developmental abnormalities, including NTD [32,33]. The results of the present study showed that the median of folate (10.7 ng/mL) and vitamin B12 (325.0 pg/mL) in pregnant women were higher than those reported by
et al. suggested, demonstrated that et al. Nutrition Journal and infant urinary methylmalonic acid deficiencies, and genetic polymorphisms. vitamin B12 deficiencies, and genetic polymorphisms. vascular diseases and its increase is related to folate and cysteinemia has been considered a risk factor for increasing the levels of Hcy is also relevant [10]. Hyperhomocysteinemia 

folic acid is the reduction of NTD, the potential benefit of reducing the risk of cardiovascular disease by reducing the levels of Hcy is also relevant [10]. Hyperhomocysteinemia has been considered a risk factor for vascular diseases and its increase is related to folate and vitamin B12 deficiencies, and genetic polymorphisms.

Some population-based studies suggest that a decline in mortality related to strokes coincided with the introduction of folic acid fortification in the United States and Canada [46]. However, some meta-analysis studies that evaluated the risk of cardiovascular disease or death in patients with or without previous disease, failed to show any beneficial effect of this strategy. Apparently, for some subgroups of patients, such as those with kidney disease, supplementation may have a beneficial effect [47,48].

Our results showed a higher frequency of hyperhomocysteinemia, mainly in the elderly. Hyperhomocysteinemia may be a consequence of ageing, oxidative stress, hypertension, diabetes and dyslipidemia. These factors were common in this group and could justify the high frequency of this condition. Moreover, our results corroborate with studies that consider the reduction of folate and vitamin B12 and age as factors related to hyperhomocysteinemia [49,50].

On the other hand, hyperhomocysteinemia was nonexistent in all the children included, and multivariate analysis demonstrated the effect of vitamin B12 levels. A study performed in 207 children from the region of Campinas demonstrated that acquired factors, vitamin B12 and folate, were the most important factor in defining the levels of plasma Hcy [51].

We have also observed that Hcy levels were normal in most of the pregnant women (99.3%). Hcy levels are known to be lower in pregnant women than in non-pregnant women [52,53]. However, studies have reported that elevated Hcy levels (>15.33 μmol/L) were observed in mothers of infants with NTD [54,55]. Furthermore, several studies have also associated high levels of Hcy to a variety of adverse effects during pregnancy [56].

In lactating women, hyperhomocysteinemia was present in 5%. Ramlau-Hansen et al. demonstrated that breastfeeding mothers who did not take folic acid supplements had a higher prevalence of elevated Hcy, compared to breastfeeding mothers taking folic acid supplements, and to a control population [57]. Despite this relationship between folate and hyperhomocysteinemia in lactating women, the multivariate analysis showed no factor that might interfere with Hcy levels, and this fact can be attributed to the number of participants included.

Among the polymorphisms investigated, only MTHFR C677T was significantly associated with folate and Hcy levels in pregnant women. Folate status is well-known to play a crucial role in the development of hyperhomocysteinemia in individuals with this polymorphism [58,59]. Furthermore, Hcy levels tend to be independent of the genotype in populations having high T allele frequency (≥20%) [60,61].

No interactions of the RFC1 A80G and GCPII C1561T polymorphisms were found on folate and Hcy levels,
corroborating with previous studies. The effects of polymorphisms in folate-metabolizing genes on Hcy levels may be masked by the interaction with other polymorphisms or with environmental factors that influence folate status [62].

The frequencies of MTHFR C677T and RFC1 A80G genotypes were similar to those reported in others populations [17,62], whereas genotype frequencies of the GCPII C1561T polymorphism were different from those described in other studies [6,7].

Finally, we were able to demonstrate that Hcy levels are influenced mainly by folate and vitamin B12. Plasma Hcy may serve as an indicator of status and perhaps of the intake of vitamins such as folate and vitamin B12 [49]. These results also corroborate with previous findings where acquired factors contributed more to hyperhomocysteinemia than genetic factors [51].

In Brazil, a few studies have evaluated vitamin deficiencies after folic acid fortification, mainly in the population investigated and, therefore, we considered this analysis of an impressive number of more than 700 participants as the strength of the current study. However some limitations should be acknowledged, such as: the fact that our population is not representative of the entire country’s population which presents great diversity; the small number of children and lactating women included; plasma Hcy samples were not kept on ice until separation, and the length of time between the blood collection and plasma preparation could have a significant impact on plasma total Hcy; the lack of data from the pre-fortification era to compare with the post-fortification era; and also the lack of data regarding food-intake to correlate with folate and vitamin B12 levels. Also, we did not perform the measurements of red blood cell folate and methylmalonic acid. We could not exclude that the real impact of fortification was compromised in lactating women because this group comprised of only 60 individuals. These limitations should be considered when analyzing our data.

**Conclusion**

Folate deficiency is practically nonexistent in the post-folic acid fortification era in the studied population. However, our study suggests that screening for vitamin B12 deficiency may be particularly relevant, especially in the elderly, and the impact of the relatively high frequency of this deficiency on the overall health of our population deserves additional studies. Regarding the influence of genetic polymorphisms, we observed no evidence that RFC1 A80G and GCPII C1561T polymorphisms-influenced folate, vitamin B12 and Hcy. Finally, we confirmed that folate and vitamin B12 are important determinants of Hcy levels.

**Abbreviations**

ANVISA: National Health Surveillance Agency; GCPII: Glutamate carboxypeptidase II; Hcy: Homocysteine; HPLC: High-performance liquid chromatography; MTHFR: Methylene tetrahydrofolate reductase; NTD: Neural tube defect; RFC1: Reduced folate carrier.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

The authors’ contributions were as follows – AB: responsible for laboratory analysis, statistical analysis, interpretation of results and writing the manuscript; ACA: responsible for study design and conducting research; LFB: contributed to subject recruitment and collection data; BMF: responsible for polymorphisms analysis; AMBZ: responsible for study supervision; EVP, NFH, JMAB: responsible for interpretation of results and critically reviewed the manuscript; and all authors read and approved the final manuscript.

**Acknowledgements**

This study was supported by a grant from the National Counsel of Technological and Scientific Development (CNPq), project no 402257/2005-7. The funder had no role in the design, analysis and writing of this article.

**Author details**

1. Department of Clinical Pathology, Faculty of Medical Sciences, University of Campinas, Rua Alexander Fleming, 105, Campinas, SP 13083-881, Brazil.
2. Hematology and Hemothapy Center, University of Campinas, Rua Carlos Chagas, 480, Campinas, SP 13083-878, Brazil.
3. Department of Pediatrics, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo, 126, Campinas, SP 13083-887, Brazil.

**Received: 14 October 2014 Accepted: 9 February 2015**

**Published online: 19 February 2015**

**References**

1. Scholl TO, Johnson WG. Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr. 2000;71:1295–303.
2. de Benoist B. Conclusions of a WHO Technical Consultation on folate and vitamin B12 deficiencies. Food Nutr Bull. 2008;29:528–44.
3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202.
4. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama. 2002;288:2015–22.
5. Allen LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull. 2008;29:520–34. discussion 525–57.
6. Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, et al. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet. 2000;9:2837–44.
7. Vargas-Martinez C, Ordovas JM, Wilson PW, Selhub J. The glutamate carboxypeptidase gene II (C>T) polymorphism does not affect folate status in the Framingham Offspring cohort. J Nutr. 2002;132:1176–9.
8. Brattstrom L, Wilcken DE, Ohvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98:2520–6.
9. D’Angelo A, Coppola A, Madonna P, Femino I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case–control study of patients with early-onset thrombotic events. Thromb Haemost. 2000;83:563–70.
10. Hoey L, Mc*Nulty H, Aiskin N, Dunne A, Ward M, Pentieva K, et al. Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults. Am J Clin Nutr. 2007;86:1405–13.
11. MacFarlane AJ, Greene-Finestone LS, Shi Y. Vitamin B12 and homocysteine status in a folate-replete population: results from the Canadian Health Measures Survey. Am J Clin Nutr. 2011;94:1079–87.
12. Ministério da Saúde, Agência Nacional de Vigilância Sanitária do Brasil (ANVISA). In: Resolução RDC n° 344. 2002. http://portal.anvisa.gov.br/wps/wcm/connect/FR51a500474500668c83dc3f04c5735/RDC_344_2002.pdf?MOD=AJPERES. Accessed 18 Jun 2013.
13. Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, et al. Vitamin B12 and folate deficiency in later life. Age Ageing. 2004;33:34-41.

14. Lamers Y. Folate recommendations for pregnancy, lactation, and infancy. Ann Nutr Metab. 2011;59:32–7.

15. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem. 1999;45:290–2.

16. Froost P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.

17. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfitzer M, Rosenblatt D, et al. A polymorphism (80G→A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310–5.

18. Clarke R, Refsum H, Birks J, Evans JG, Johnston C, Sherliker P, et al. Screening for vitamin B12 and folate deficiency in older persons. Am J Clin Nutr. 2003;77:1241–7.

19. World Health Organization, Food and Agricultural Organization. Guidelines on food fortification with micronutrients. Geneva, Switzerland: WHO/FAO; 2006.

20. Xavier JM, Costa FF, Annichino-Bizzacchi JM, Saad ST. High frequency of vitamin B12 deficiency in a Brazilian population. Public Health Nutr. 2010;13:1191–7.

21. Metz J. A high prevalence of biochemical evidence of vitamin B12 or folate deficiency does not translate into a comparable prevalence of anemia. Food Nutr Bull. 2008;29:754–85.

22. Lindenbaum J, Allen RH. Clinical spectrum and diagnosis of folate deficiency. In: Bailey LB, editor. Folate. In health and disease. New York: Marcel Dekker, Inc; 1995. p. 43–73.

23. Couris C. Prevalence of deficiency of vitamina B12 is a ãcido fólico e sua associacãão com anemia em idosos atendidos em um Hospital Universitário. http://repository.ucps.br/dspace/bitstream/10923/3771/1/0004284555-Texto%2BCompleto.pdf. (2013). Accessed 20 Jun 2013.

24. Tiemeier H, van Tuil JR, Hoffman A, Meijer J, Kiliaan AJ, Breteler MM, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159:2099–101.

25. Seshadri S, Costa RJ, Egan DF, Dumesnil JG, Breteler MM, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002;346:476–85.

26. Hin H, Clarke R, Sherliker P, Atreyebi W, Emmens K, Birks J, et al. Clinical relevance of low serum vitamin B12 concentrations in older people: the Barnothy B2 study. Age Ageing. 2006;35:416–22.

27. Carmel R. Biomarkers of cobalamin (vitamin B12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and hokotranscobalamin II. Am J Clin Nutr. 2011;94:484S–58.

28. Villamor E, Mora-Plazas M, Forero Y, Lopez-Arana S, Baylin A. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159:2099–101.

29. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, et al. A polymorphism (80G- > A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310–5.

30. Velzing-Aarts FV, Holm PI, Fokkema MR, van der Dijks FP, Ueland PM, Musket FA. Plasma choline and betaine and their relation to plasma homocysteine in normal pregnancy. Am J Clin Nutr. 2005;81:335–9.

31. Wallace JM, Bonham MP, Slaun J, Duffy EM, Robson PJ, Ward M, et al. Homocysteine concentration, related B vitamins, and betaine in pregnant women recruited to the Seychelles Child Development Study. Am J Clin Nutr. 2008;87:391–7.

32. Specker BL, Black A, Allen L, Morrow F. Vitamin B12: low milk concentrations are related to low serum concentrations in vegetarian women and to their methylenonic acidemia in their infants. Am J Clin Nutr. 1990;52:1073–6.

33. Stabler SP, Stabler SS, Barnabé RT, Weatherill N, Seedorf U, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:17–9.

34. Stabler SP, Barnabé RT, Weatherill N, Seedorf U, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:17–9.
60. Gueant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, et al. Prevalence of methylenetetrahydrofolate reductase 677 T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr. 2006;83:701–7.

61. Yang QH, Botto LD, Gallagher M, Friedman JM, Sanders CL, Koontz D, et al. Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank. Am J Clin Nutr. 2008;88:232–46.

62. Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr. 2006;83:708–13.